| 1 |
31567201 | Clinical Experience With 75-mg Dose of Erlotinib for Mutated Metastatic EGFR Non-small Cell Lung Cancer. | 2021 Jul-Aug 01 |
3 |
| 2 |
31559898 | BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment. | 2020 |
1 |
| 3 |
31595681 | FTIR spectra signatures reveal different cellular effects of EGFR inhibitors on nonsmall cell lung cancer cells. | 2020 Mar |
1 |
| 4 |
31730733 | Complete remission of membranous nephropathy in a patient with lung adenocarcinoma treated with erlotinib. | 2020 Apr |
2 |
| 5 |
31747091 | Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies. | 2020 May |
1 |
| 6 |
31778239 | Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer. | 2020 Apr |
2 |
| 7 |
31812754 | Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. | 2020 Mar |
1 |
| 8 |
31820199 | Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study. | 2020 Feb |
4 |
| 9 |
31838083 | Nerve growth factor (NGF)-TrkA axis in head and neck squamous cell carcinoma triggers EMT and confers resistance to the EGFR inhibitor erlotinib. | 2020 Mar 1 |
2 |
| 10 |
31885349 | Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients. | 2020 Apr |
1 |
| 11 |
31894866 | Pharmacophore modeling, 3D-QSAR, synthesis, and anti-lung cancer evaluation of novel thieno[2,3-d][1,2,3]triazines targeting EGFR. | 2020 Feb |
1 |
| 12 |
31936715 | HB-EGF-EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma. | 2020 Jan 10 |
1 |
| 13 |
31938054 | The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor. | 2020 |
1 |
| 14 |
31954111 | The Role of Self-Nanoemulsifying Drug Delivery Systems of CDODA-Me in Sensitizing Erlotinib-Resistant Non-Small Cell Lung Cancer. | 2020 Jun |
1 |
| 15 |
31960422 | Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function. | 2020 Nov |
1 |
| 16 |
31969600 | Delineation of cell death mechanisms induced by synergistic effects of statins and erlotinib in non-small cell lung cancer cell (NSCLC) lines. | 2020 Jan 22 |
1 |
| 17 |
31972351 | Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer. | 2020 May |
1 |
| 18 |
32005679 | Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. | 2020 Jan 31 |
1 |
| 19 |
32021306 | Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases. | 2020 |
1 |
| 20 |
32022097 | Poly(ester-thioether) microspheres co-loaded with erlotinib and α-tocopheryl succinate for combinational therapy of non-small cell lung cancer. | 2020 Feb 26 |
3 |
| 21 |
32070872 | Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab. | 2020 May |
1 |
| 22 |
31554377 | Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib. | 2019 Sep 1 |
2 |
| 23 |
31555526 | Effective targeted therapy based on dynamic monitoring of gene mutations in non-small cell lung cancer. | 2019 Aug |
1 |
| 24 |
31571631 | A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients. | 2019 Jul |
1 |
| 25 |
31591063 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. | 2019 Dec |
1 |
| 26 |
31671561 | FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management. | 2019 Oct 30 |
1 |
| 27 |
31691527 | MYST1/KAT8 contributes to tumor progression by activating EGFR signaling in glioblastoma cells. | 2019 Dec |
2 |
| 28 |
31695757 | Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas. | 2019 |
2 |
| 29 |
31698647 | The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis. | 2019 Aug 28 |
1 |
| 30 |
31740864 | Concurrent radiotherapy and chemotherapy with erlotinib followed by maintenance erlotinib in patients with Epidermal Growth Factor Receptor mutation- positive adenocarcinoma lung. | 2019 Nov |
4 |
| 31 |
31762748 | The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance. | 2019 Sep-Dec |
1 |
| 32 |
31772161 | Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRβ-IL-6 axis in MUC1-positive cervical cancer. | 2019 Nov 26 |
3 |
| 33 |
31803256 | Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients. | 2019 |
1 |
| 34 |
31827134 | MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma. | 2019 Dec 11 |
1 |
| 35 |
31843782 | Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib. | 2019 Dec 15 |
2 |
| 36 |
31857948 | Epidermal growth factor receptor first generation tyrosine-kinase inhibitors. | 2019 Nov |
1 |
| 37 |
32016064 | Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line? | 2019 Dec |
1 |
| 38 |
32038917 | Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer. | 2019 Dec |
1 |